$0.01
0.00% yesterday
Nasdaq, Jun 06, 07:26 pm CET
ISIN
US30048L1044
Symbol
EVFM
Sector
Industry

Evofem Biosciences, Inc. Stock price

$0.01
+0.00 11.63% 1M
+0.00 1.05% 6M
-0.00 3.03% YTD
-0.00 23.20% 1Y
-6,468.74 100.00% 5Y
-74,362.49 100.00% 10Y
-134,999.99 100.00% 20Y
Nasdaq, Closing price Fri, Jun 06 2025
+0.00 0.00%
ISIN
US30048L1044
Symbol
EVFM
Sector
Industry

Key metrics

Market capitalization $1.09m
Enterprise Value $46.42m
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 2.79
P/S ratio (TTM) P/S ratio 0.07
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 3.75%
Revenue (TTM) Revenue $16.61m
EBIT (operating result TTM) EBIT $-4.51m
Free Cash Flow (TTM) Free Cash Flow $-3.45m
Cash position $350.00k
EPS (TTM) EPS $0.00
Short interest 11.01%
Show more

Is Evofem Biosciences, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,823 stocks worldwide.

Evofem Biosciences, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Evofem Biosciences, Inc.:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Evofem Biosciences, Inc.:

Buy
100%

Financial data from Evofem Biosciences, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
17 17
4% 4%
100%
- Direct Costs 3.52 3.52
40% 40%
21%
13 13
28% 28%
79%
- Selling and Administrative Expenses 21 21
16% 16%
124%
- Research and Development Expense 1.25 1.25
58% 58%
8%
-3.66 -3.66
78% 78%
-22%
- Depreciation and Amortization 0.84 0.84
250% 250%
5%
EBIT (Operating Income) EBIT -4.51 -4.51
74% 74%
-27%
Net Profit -3.16 -3.16
107% 107%
-19%

In millions USD.

Don't miss a Thing! We will send you all news about Evofem Biosciences, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Evofem Biosciences, Inc. Stock News

Neutral
PRNewsWire
17 days ago
— Pharma 1 Targets Mid-2025 Regulatory Submission in UAE for SOLOSEC to Treat Bacterial Vaginosis and Trichomoniasis — SAN DIEGO , May 21, 2025 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. (OTCPK: EVFM) and private Emirati health care company Pharma 1 Drug Store LLC have signed a License and Supply Agreement for the Middle East rights to SOLOSEC® (secnidazole) 2 g oral gran...
Neutral
PRNewsWire
23 days ago
SAN DIEGO , May 15, 2025 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. (OTCPK: EVFM), today announced financial results for the first quarter ended March 31, 2025. "Quarterly fluctuations are normal for our business, which is why we focus on driving annual growth," said Saundra Pelletier, Evofem's CEO.
Neutral
PRNewsWire
about 2 months ago
SAN DIEGO , April 14, 2025 /PRNewswire/ -- Evofem Biosciences, Inc., (OTCQB: EVFM) today announced that members of its management team will present at the upcoming Emerging Growth Conference as follows: Date:                      Thursday, April 17, 2025 Time:                    10:50 – 11:20 am ET (7:50 – 8:20 am PT) Live webcast:          https://evofem.investorroom.com/EmergingGrowth2025 or ...
More Evofem Biosciences, Inc. News

Company Profile

Evofem Biosciences, Inc. develops therapeutic solutions to meet sexual and reproductive health needs of women. Its product include Amphora Contraceptive for the prevention of pregnancy, antimicrobial drug product for the prevention of sexually transmitted infections and Antimicrobial Drug product to prevent the reoccurrence of bacterial vaginosis. The company was founded in 2007 and is headquartered in San Diego, CA.

Head office United States
CEO Saundra Pelletier
Employees 32
Founded 2007
Website www.evofem.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today